lonapegsomatropin-tcgd (Skytrofa)

Indications

• treatment of growth hormone deficiency in children > 1 year of age & > 11.5 kg

Contraindications

• children with closed epiphysis
• Prader-Willi syndrome with obesity or respiratory insufficiciency

Dosage

• 0.24 mg/k SQ injection into abdomen, buttocks or thigh with regular rotation

lyophilized powder available in single-dose, dual-chamber, prefilled cartridges 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg & 13.3 mg

Adverse effects

• increased risk of neoplasms
• glucose intolerance & diabetes mellitus
• intracranial hypertension
• fluid retention (edema, arthralgia, carpal tunnel syndrome)
• hypoadrenalism
• pancreatitis
• progression of preexisting scoliosis
• slipped capital femoral epiphysis
• nausea/vomiting, diarrhea

Mechanism of action

• human growth hormone